Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Goldman Sachs Maintains Buy on Calumet Specialty Prods, Raises Price Target to $19

Author: Benzinga Newsdesk | December 14, 2023 09:39am
Goldman Sachs analyst Neil Mehta maintains Calumet Specialty Prods (NASDAQ:CLMT) with a Buy and raises the price target from $17 to $19.

Posted In: CLMT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist